Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …

Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-
altering. We initiated a phase 2 study in which patients with MIBC received four cycles of …

This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

Context We present an overview of the updated 2023 European Association of Urology
(EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …

Context Management of bladder cancer (BC) is primarily driven by stage, grade, and
biological potential. Knowledge of each is derived using clinical, histopathological, and …

Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic
muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of …

Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …

Background Tri-modality therapy (TMT) is a recognized treatment strategy for selected
patients with muscle-invasive bladder cancer (MIBC). Objective Report long-term outcomes …